Suppr超能文献

溶栓治疗初始阶段的纤溶酶抑制剂与纤维蛋白原降解——α2-抗纤溶酶测定问题

Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination.

作者信息

Noll G, Lämmle B, Duckert F

出版信息

Thromb Haemost. 1984 Jul 29;51(3):334-7.

PMID:6238441
Abstract

During the first 3 hr of thrombolytic treatment with porcine plasmin (p-PL) or streptokinase (SK) a rapid decrease of clottable fibrinogen with generation of large amounts of fibrin(-ogen) degradation products (FDP) are found. alpha 2-antiplasmin (alpha 2AP) is rapidly neutralized. Whereas in patients treated with SK more than half of the original plasminogen was consumed, its level remained unchanged during p-PL infusion. When alpha 2AP reaches values below some 20%, spontaneous amidolytic activity towards S-2251 representing either PL-alpha 2-macroglobulin- or SK-plasminogen-complex activity appears. This activity has to be considered in the alpha 2AP assay in order to avoid underestimation of this inhibitor.

摘要

在用猪纤溶酶(p-PL)或链激酶(SK)进行溶栓治疗的最初3小时内,可发现可凝纤维蛋白原迅速减少,并产生大量纤维蛋白(原)降解产物(FDP)。α2-抗纤溶酶(α2AP)迅速被中和。在用SK治疗的患者中,超过一半的原始纤溶酶原被消耗,而在输注p-PL期间其水平保持不变。当α2AP的值低于约20%时,会出现对S-2251的自发酰胺水解活性,这代表PL-α2-巨球蛋白或SK-纤溶酶原复合物的活性。在α2AP检测中必须考虑这种活性,以避免低估这种抑制剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验